SCHEMBL3028484

SCHEMBL3028484

CSc1cc(C(F)(F)F)ccc1C(=O)Cl

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 4/20 0.46
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
SLC6A9 P48067 1/20 0.43
CFTR P13569 1/20 0.43
USP2 O75604 1/20 0.42
CYP2C19 P33261 1/20 0.42
GAA P10253 1/20 0.39
DDR1 Q08345 1/20 0.37
SORT1 Q99523 4/20 0.36
CES1 P23141 1/20 0.36
PDE2A O00408 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28095379 0.86 CES2 (0.49) CES2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6751351 0.85 CES2 (0.47) CES2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL427104 0.85 ALDH1A1 (0.57) CES2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL29683463 0.85 CES2 (0.47) CES2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2325301 0.83 KDM4E (0.47) CES2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL18544164 0.83 CES2 (0.42) CES2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL5843160 0.81 CFTR (0.63) CES2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL3023134 0.80 CES2 (0.53) CES2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL11752106 0.78 SLC6A9 (0.47) CES2ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL8047749 0.77 CES2 (0.41) CES2ALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067911-B2 Piperidine derivatives HOFFMANN-LA ROCHE INC. (US) 2015-06-30 US disclosed
EP-2391603-B1 AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
US-20130158050-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed
US-20100197715-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158050-A1 PIPERIDINE DERIVATIVES GRIN1, GRIN2A, GRIN2C CES2 1184/4885ALDH1A1 55/4885KDM4E 2562/4885
US-20100197715-A1 PIPERIDINE DERIVATIVES GRIN1, GRIN2A, GRIN2C CES2 1184/4885ALDH1A1 55/4885KDM4E 2562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.